Literature DB >> 15188510

Intestinal microecology and quality of life in irritable bowel syndrome patients.

Jian-Min Si1, Ying-Cong Yu, Yu-Jing Fan, Shu-Jie Chen.   

Abstract

AIM: It has been noticed that gastroenteritis or dysentery plays a role in pathogenesis of irritable bowel syndrome (IBS), and antibiotics can increase functional abdominal symptoms, both of which may be partly due to intestinal flora disorders. This study was to determine the change of gut flora of IBS, a cluster of abdominal symptoms. Because of the chronic course and frequent occurrence of the disease, IBS patients suffered much from it. So the quality of life (Qol) of IBS patients was also evaluated in this study.
METHODS: Twenty-five Rome II criteria-positive IBS patients were recruited, and 25 age and gender-matched healthy volunteers were accepted as control. The fecal flora, including Lactobacillus, Bifidobacterium, Bacteroides, C. perfringens Enterobacteriacea and Enterococus, were analyzed quantitatively and qualitatively. We also calculated the ratio of Bifidobacterium to Enterobacteriaceae (B/E ratio) in both IBS patients and controls. In both groups, the data were further analyzed based on age difference, and comparisons were made between the younger and elder subgroups. We also evaluated the quality of life (QoL) of IBS patients and the control group using the Chinese version of SF-36 health questionnaire.
RESULTS: In IBS patients, the number of fecal Bifidobacterium was significantly decreased and that of Enterobacteriaceae was significantly increased compared with that in healthy controls (both P<0.05). The mean microbial colonization resistance (CR) of the bowel in IBS patients was smaller than 1, making a significant difference compared with that in control which was more than 1 (P<0.01). There was no significant difference in gut flora between two subgroups. While in control, the elder subgroup presented more Enterobacteriacea than the younger one (P<0.05). Compared with the control group, IBS patients had significantly lower scores on all SF-36 scales, with the exception of physical functioning. However, there was no significant correlation between quality of life and enteric symptoms in IBS patients.
CONCLUSION: There are intestinal flora disorders in IBS patients, which may be involved in triggering the IBS-like symptoms. IBS patients experience significant impairment in QoL, however, the impairment is not caused directly by enteric symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15188510      PMCID: PMC4572273          DOI: 10.3748/wjg.v10.i12.1802

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  [Strengthening research on etiology and treatment of irritable bowel syndrome].

Authors:  Guo-ming Xu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2003-02

2.  History of recognition and measurement of colonization resistance of the digestive tract as an introduction to selective gastrointestinal decontamination.

Authors:  D van der Waaij
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

3.  Antibiotics increase functional abdominal symptoms.

Authors:  P R Maxwell; E Rink; D Kumar; M A Mendall
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

4.  Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

Authors:  B A Hahn; S Yan; S Strassels
Journal:  Digestion       Date:  1999 Jan-Feb       Impact factor: 3.216

Review 5.  Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials.

Authors:  R B Lydiard; S A Falsetti
Journal:  Am J Med       Date:  1999-11-08       Impact factor: 4.965

6.  Long-term ingestion of lactosucrose increases Bifidobacterium sp. in human fecal flora.

Authors:  T Ohkusa; Y Ozaki; C Sato; K Mikuni; H Ikeda
Journal:  Digestion       Date:  1995       Impact factor: 3.216

7.  Impact of irritable bowel syndrome on personal relationships and working practices.

Authors:  D B Silk
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-11       Impact factor: 2.566

8.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

9.  Gastroparesis and small bowel dysmotility in irritable bowel syndrome.

Authors:  P R Evans; Y T Bak; B Shuter; R Hoschl; J E Kellow
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

10.  Abnormal colonic fermentation in irritable bowel syndrome.

Authors:  T S King; M Elia; J O Hunter
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

View more
  65 in total

1.  Do probiotics improve symptoms in patients with irritable bowel syndrome?

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

3.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

Review 4.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

5.  Gut microbiota of healthy elderly NSAID users is selectively modified with the administration of Lactobacillus acidophilus NCFM and lactitol.

Authors:  Marika Björklund; Arthur C Ouwehand; Sofia D Forssten; Janne Nikkilä; Kirsti Tiihonen; Nina Rautonen; Sampo J Lahtinen
Journal:  Age (Dordr)       Date:  2011-08-19

Review 6.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

7.  Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.

Authors:  Anna Lyra; Teemu Rinttilä; Janne Nikkilä; Lotta Krogius-Kurikka; Kajsa Kajander; Erja Malinen; Jaana Mättö; Laura Mäkelä; Airi Palva
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

8.  Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia.

Authors:  David E Saslowsky; Noriyuki Tanaka; Krishna P Reddy; Wayne I Lencer
Journal:  FASEB J       Date:  2008-09-26       Impact factor: 5.191

9.  From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome.

Authors:  Oscar Rodríguez-Fandiño; Joselín Hernández-Ruiz; Max Schmulson
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

10.  Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Authors:  Lotta Krogius-Kurikka; Anna Lyra; Erja Malinen; Johannes Aarnikunnas; Jarno Tuimala; Lars Paulin; Harri Mäkivuokko; Kajsa Kajander; Airi Palva
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.